MDIT (Medite Cancer Diagnostics) EPS (Basic) : $-0.15 (TTM As of Sep. 2018)

View and export this data going back to . Start your Free Trial

What is Medite Cancer Diagnostics EPS (Basic)?

Medite Cancer Diagnostics's basic earnings per share (Basic EPS) for the three months ended in Sep. 2018 was $-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.15.

Medite Cancer Diagnostics's EPS (Diluted) for the three months ended in Sep. 2018 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.15.

Medite Cancer Diagnostics's EPS without NRI for the three months ended in Sep. 2018 was $-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2018 was -0.15.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Medite Cancer Diagnostics EPS (Basic) Historical Data

The historical data trend for Medite Cancer Diagnostics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medite Cancer Diagnostics EPS (Basic) Chart

Medite Cancer Diagnostics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

EPS (Basic)

Get a 7-Day Free Trial

-0.04

-0.05

-0.11

-0.26

Medite Cancer Diagnostics Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
EPS (Basic)	Get a 7-Day Free Trial															-0.06	-0.09	-0.04	-0.01	-0.01

Medite Cancer Diagnostics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Medite Cancer Diagnostics's Basic EPS for the fiscal year that ended in Dec. 2017 is calculated as

Basic EPS (A: Dec. 2017 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-6.811	-	0.091)	/	26.436
	=	-0.26

Medite Cancer Diagnostics's Basic EPS for the quarter that ended in Sep. 2018 is calculated as

Basic EPS (Q: Sep. 2018 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.735	-	0.022)	/	72.368
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.15

Medite Cancer Diagnostics (OTCPK:MDIT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Medite Cancer Diagnostics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Medite Cancer Diagnostics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Medite Cancer Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medite Cancer Diagnostics Inc (OTCPK:MDIT) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

10524 Moss Park Road, Suite 204-357, Orlando, FL, USA, 32832

Website

http://www.medite-group.com

Medite Cancer Diagnostics Inc is a US-based company that specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology, and marketing of molecular biomarkers. The company manufactures medical devices and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company operates through a single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.

Executives

Lewis William Austin Iv	director, 10 percent owner	201 E 87TH STREET, APT 5H, NEW YORK NY 10128
John H Abeles	director	2365 NW 41ST STREET BOCA RATON FL 33431
Joel S Kanter	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Clinton Severson	director	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587

Medite Cancer Diagnostics Headlines

No Headlines